Sign in Create account

AstraZeneca Pharma India Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ASTRAZEN BSE: 506820
₹6186.00
▼ -68.50 (-1.10%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
78/100
Strong
Valuation
—/100
Expensive
Momentum
5/100
Bearish

QVM read Quality, pricey and fading Quality Strong, Valuation Expensive, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹15,465 Cr
PE (TTM)
91.2
Industry median 36.1 (152 companies)
Price to Book
17.7
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
8.76%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
-16.2
Relative return vs Sector, qtr %
-24.3
Free Cash Flow
₹-19 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-32.06%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
20.54%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
34.94%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-32.06%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
29.73%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.76
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
40.90
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
5.56%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
7.72%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
9.62%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
9.43%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
25.48%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
21.49%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (21.5%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.1%
Low 6120.5000 · High 6289.0000
1W return
-7.8%
Low 6120.5000 · High 6706.0000
1M return
-11.0%
Low 6120.5000 · High 7062.0000
52W return
-32.9%
Low 6120.5000 · High 9849.5000
Lifetime High ₹10509.5000 (June 13, 2025)
Lifetime Low ₹435.3500 (Jan. 22, 2008)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
6342.2
10D
6480.9
20D
6687.8
50D
7169.5
100D
7618.7
200D
8212.8

Delivery and volume

Day avg. delivery
45.7%
Week avg. delivery
74.4%
Month avg. delivery
63.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

6198.50
Pivot
First resistance6276.50
Second resistance6367.00
Third resistance6445.00
First support6108.00
Second support6030.00
Third support5939.50
Day RSI16.1
Day MFI21.8
Day MACD-276.11
Day MACD signal-256.78

Beta

1M0.88
3M0.78
1Y0.55
3Y0.56

Price change analysis

↓ -11.0%
Over 1 Month
LowHigh
6120.507062.00
↓ -24.3%
Over 3 Months
LowHigh
6120.508510.00
↓ -21.2%
Over 6 Months
LowHigh
6120.509150.00
↓ -32.9%
Over 1 Year
LowHigh
6120.509849.50
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 91.2 (own history: 82.5–243.3)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹683 Cr
Net profit (June 30, 2026)
₹38 Cr
Basic EPS (June 30, 2026)
₹15.1700

Ranks #37 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter75.00%
  • Mutual funds6.01%
  • FII/FPI2.68%
  • Other DII0.07%
  • Public16.24%

Largest holders

NameCategoryShares %Shares
AstraZeneca Pharmaceuticals ABPromoter75.0000%18750000
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND(VARIOUS SCHEMES)Public2.8900%722443
TEJAS BHALCHANDRA TRIVEDIPublic2.6800%669078
SHIVANI TEJAS TRIVEDIPublic2.3300%583606
ICICI PRUDENTIAL - VARIOUS SCHEMESPublic1.3900%346441

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 75.00% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 2.78% to 2.68% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 5.66% to 6.01% in Jun 2026 qtr

19 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 0 insider trades, 3 SAST, 0 pledge events →

All insider and SAST disclosures →

Deals (Bulk & Block)

All 14 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
7 Oct 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 125,166 7887.1600 NSE
7 Oct 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 125,166 7884.4100 NSE
30 Sep 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 127,119 7804.9600 NSE
30 Sep 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 127,119 7802.0000 NSE
24 Sep 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 131,308 7506.3600 NSE
24 Sep 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 131,308 7499.1700 NSE
19 Sep 2022 ISHARES MSCI INDIA SMALL-CAP ETF Block Buy 6,542 3152.5500 BSE
19 Sep 2022 ISHARES INDIA SC MAURITIUS COMPANY Block Sell 6,542 3152.5500 BSE
19 Sep 2022 ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 74,097 3152.5500 BSE
19 Sep 2022 ISHARES CORE MSCI EMERGING MARKETS ETF Block Buy 74,097 3152.5500 BSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹36.00 per share
Dividend yield 0.58%
Ex-dateSubjectPer share (₹)Record date
31 Jul 2026 Dividend - Rs 36 Per Share 36.0000 31 Jul 2026
18 Jul 2025 Dividend - Rs 32 Per Share 32.0000 18 Jul 2025
5 Jul 2024 Dividend - Rs 24 Per Share 24.0000 5 Jul 2024
14 Jul 2023 Dividend - Rs 16 Per Share 16.0000 14 Jul 2023
7 Jul 2022 Dividend - Rs 8 Per Share 8.0000 8 Jul 2022
18 Aug 2021 Interim Dividend - Rs 2 Per Share 2.0000 20 Aug 2021
20 Aug 2020 Interim Dividend - Rs 2 Per Share 2.0000 21 Aug 2020
20 Aug 2019 Interim Dividend - Re 1 Per Share 1.0000 21 Aug 2019
7 Jul 2011 Dividend-Rs.10/- Per Share 10.0000 —
6 May 2010 Dividend-Rs.10/- Pr Share 10.0000 —

Corporate Actions

Full history (24 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
4 Jan 2008BONUSSch Of Agmt- Bonus Deb1:1
15 Jun 2006SPLITFv Split Rs.10/- To Rs.2/
—NAME_CHANGEName changed from Astra - IDL Ltd to AstraZeneca Pharma India Ltd.
30 Aug 2018OTHER Annual General Meeting
4 Sep 2017OTHER Annual General Meeting
2 Aug 2016OTHER Annual General Meeting
20 Aug 2015OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
26 May 2026 Financial Results/Dividend Yes
11 Feb 2026 Financial Results Yes
7 Nov 2025 Financial Results Yes
14 Aug 2025 Financial Results Yes

Corporate Announcements

All 706 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
18 Sep 2026 Company Update AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
18 Sep 2026 Action(s) taken or orders passed AstraZeneca Pharma India Limited has informed the Exchange about Action(s) taken or orders passed
15 Sep 2026 Company Update AstraZeneca Pharma India Ltd - 506820 - Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Resignation Of Senior Management Personnel
15 Sep 2026 Insider Trading / SAST AstraZeneca Pharma India Ltd - 506820 - Closure of Trading Window
15 Sep 2026 Resignation of Director/KMP/SMP AstraZeneca Pharma India Limited has informed the Exchange about Resignation of Director/KMP/SMP
15 Sep 2026 Trading Window AstraZeneca Pharma India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
15 Sep 2026 General Updates AstraZeneca Pharma India Limited has informed the Exchange about General Updates
2 Sep 2026 General Updates AstraZeneca Pharma India Limited has informed the Exchange about General Updates
25 Aug 2026 Action(s) taken or orders passed AstraZeneca Pharma India Limited has informed the Exchange about Action(s) taken or orders passed
24 Aug 2026 General Updates AstraZeneca Pharma India Limited has informed the Exchange about General Updates

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (40.9x)
  • Healthy liquidity (Current Ratio 1.76)
  • Strong revenue growth YoY (29.7%)

Weaknesses

  • Declining profit YoY (-32.1%)

Opportunities

  • RSI in oversold territory (16.1) -- a technical rebound zone

Threats

  • PE above 35 (91.2) -- priced for continued strong execution
  • Down 32.9% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about AstraZeneca Pharma India Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.